Literature DB >> 30280116

Review of the prevalence of postnatal depression across cultures.

Siti Roshaidai Mohd Arifin1, Helen Cheyne2, Margaret Maxwell2.   

Abstract

The purpose of this review was to examine articles related to recent epidemiological evidence of the prevalence of maternal postnatal depression (PND) across different countries and cultures and to identify specific epidemiological studies that have been carried out exclusively in Malaysia on the prevalence of maternal PND. The review was undertaken in two stages, an initial review and an updated review. At both stages systematic literature searches of online databases were performed to identify articles on the prevalence of maternal PND. A total of 124 articles concerning research conducted in more than 50 countries were included in the final analysis. There were wide variations in the screening instruments and diagnostic tools used although the Edinburgh Postnatal Depression Scale (EPDS) was the most common instrument applied to identify PND. The prevalence of maternal PND ranged from 4.0% to 63.9%, with Japan and America recording the lowest and highest rates, respectively. Within continents, a wide variation in reported prevalence was also found. The reported rates of maternal PND in Malaysia were much higher than that previously documented with a range of 6.8-27.3%. This review indicated that the widely cited prevalence of maternal PND of 10-15% underestimates rates of PND worldwide. The reasons for this variability may not be fully explained by review methods. Future studies should evaluate the nature of women's PND experiences across cultures to explain these wide variations.

Entities:  

Keywords:  cultures; postnatal depression; postnatal women; prevalence

Year:  2018        PMID: 30280116      PMCID: PMC6141558          DOI: 10.3934/publichealth.2018.3.260

Source DB:  PubMed          Journal:  AIMS Public Health        ISSN: 2327-8994


Introduction

Postnatal depression (PND) is one of the most common causes of maternal distress representing a considerable public health problem affecting the mother, her baby, and her family [1]. Within the postnatal period, there is an increase in the physical and emotional demands on the woman and the debility associated with PND may impinge on her capacity as a mother for example, to care for and bond with her new-born. In some instances the woman may be less engaged, and may even react negatively towards the child [2]. Without diagnosis and treatment, maternal PND may affect her ability to participate in normal activities and interfere with her family and other social relationships. These problems can compromise maternal-infant relationships which may be associated with poor child cognitive and behavioral and social development [3]–[6]. Partners of women with PND have also been shown to be at risk of poor mental health [7]–[9]. Although these experiences are commonly shared by women across cultures, experiences of PND are not fully shared or similarly expressed by women across the world, with some experiences being more common in certain cultures or countries. For instance, whilst social circumstance and biophysical stressors were described as factors contributing to PND in many countries, issues of culture and traditions were more common in Asian women [10],[11]. Considering ways of reducing their distress, Asian women were more likely to describe religious beliefs and social support, whereas European women talked about recognizing their own needs and personal adjustment such as keeping busy and getting out the house every day [10]–[17]. These findings suggest that culture can affect the way the women interpret their experience of PND, the causes of PND and influences on their coping strategies. Culture can play an important role in women's experience of pregnancy and after childbirth as it is comprised of several shared ideas, values, perspectives, beliefs, and “perceived standards” for emotional and behavioral responses [18]. The prevalence of PND is highly variable in non-western countries and its manifestations may vary across cultures [19],[20]. For instance, previous reviews have shown that the prevalence of PND ranged widely from 0 to 60% globally, and from 3.5 to 63.3% in Asian countries [20],[21]. These findings suggest that there is a link between the conceptualization of PND and culture yet there is a lack of recent evidence on PND across different countries. Taking an example of Malaysia as an example of a non-western country the aims of this review are twofold: To provide recent epidemiological evidence of the prevalence of maternal PND across different countries and cultures. To identify specific epidemiological studies that have been carried out exclusively in Malaysia on the prevalence of maternal PND.

Methods

The review was undertaken in two stages: The initial review and a more recent updated review. The initial review was conducted based on the search terms used by Halbreich and Karkun [21]. The updated review was conducted with an improved search strategy. Both reviews were conducted by the first author (MA). Articles were selected based on the inclusion and exclusion criteria (Table 1). Discussions with the second and third author were conducted to resolve any discrepancies in decisions about excluding or including articles.
Table 1.

Initial and updated review of prevalence of postnatal depression.

Initial reviews (2006–2014)Updated reviews (2010–2016)
DatabasesCINAHL, MEDLINE, PubMed, PsycArticles, PsycINFO, Web of Science, and The Cochrane Library.CINAHL, MEDLINE, PubMed, PsycINFO and ASSIA.
KeywordsPrevalence, postnatal depression, and postpartum depression.Incidence, prevalence, postnatal depression, postpartum depression, depression, maternal mental health, depressive disorders, puerperal disorders, emotional distress, low mood disorders, after childbirth, psychological distress.
Inclusion criteriaPeer reviewed articles published from 2006–2014, studies that report prevalence of PND within 1–12 months following childbirth, full text available, and English/Malay language publications.Peer reviewed articles published from 2010–2016, studies that report prevalence of PND within 1–12 months following childbirth, and English/Malay language publications.
Exclusion criteriaReview papers, and PND and/or postnatal women were not the focus of the study.Review papers, PND and/or postnatal women were not the focus of the study, studies within psychiatric populations, and studies that were conducted among high risk groups of women.
Total studies included in the final analysis39104

Search strategies

Electronic databases used in both two reviews were: CINAHL, MEDLINE, PubMed, and PsycINFO. In the updated review, PsycArticles were not used as articles in this database are also available in PsycINFO, whereas Web of Science and The Cochrane Library were not used as articles in both databases are also available in ASSIA. The search strategy for both reviews can be seen in Figure 1. Searches were conducted using the following keywords: Incidence, prevalence, postnatal depression, postpartum depression, depression, maternal mental health, depressive disorders, puerperal disorders, emotional distress, low mood disorders, after childbirth, psychological distress. Keywords were also combined using AND and OR to identify as many articles as possible on the prevalence of maternal PND.
Figure 1.

Flow diagram of the search strategy for prevalence of postnatal depression (initial review).

Inclusion and exclusion criteria

In both reviews, PND is defined as “any depressive symptomatology occurring within the first postnatal year”. However, to avoid inclusion of postnatal blues in the reported prevalence, the time frame used in these reviews was 1–12 months following childbirth. For studies that assessed the prevalence at more than one-time point only prevalence within 1–12 following childbirth was included in this review. For studies that included more than one time point within 1–12 months all reported prevalence was included in the review. Studies undertaken within the year 2006–2016 were included because they were more likely to reflect the current state of knowledge on PND. The largest review involving worldwide studies by Halbreich and Karkun [21] only included articles up to 2005. High risk populations (some population groups are at considerably higher risk of developing PND than others such as women with unsuccessful attempted abortions or women who gave birth prior to an earthquake) and psychiatric population (women with known psychiatric diagnosis such as schizophrenia or anxiety disorders) were excluded because their risks developing PND may reach 40–60% [22]. This present review was conducted using scoping review methodology reported in Joanna Briggs Institute Reviewers' Manual 2015 Methodology for JBI Scoping Reviews [23].

Results

Findings presented in this section are based on the summary of both the initial and updated reviews. The initial review identified 7896 articles, screened 80 abstracts, and identified 68 full text papers for inclusion. The updated review identified 4828 articles, screened 411 abstracts, and identified 156 full text papers for inclusion. Figures 1 and 2 show the flow diagrams of search strategies used in the initial and updated reviews, respectively.
Figure 2.

Flow diagram of search strategy for prevalence of postnatal depression (updated review).

The most common reasons for excluding articles in both reviews were that they; did not relate to PND/did not publish within 2006–2014 (initial review) or 2010–2016 (updated review), were not conducted within 1–12 months following childbirth, were not focused on maternal PND, did not report prevalence of maternal PND, were review papers, were conducted among high risk groups of women, were not in English/Malay language, were duplicate studies, were within a psychiatric population, and were conducted among fathers with PND. Whilst the initial review finally included 39 articles, 102 articles were included in the updated review. A total of 17 studies were duplicates (found in both reviews) and ultimately 124 articles were included in the final analysis. These studies were conducted in more than 50 countries. Described in relation to continents, 58 studies were conducted in Asia, 22 in North America and seven in South America, 23 in Europe, nine in Australia and New Zealand, and five in Africa. Data extracted from each included study were screening instruments, sample size, time of assessment, study design, study setting, and prevalence of maternal PND (Table 2).
Table 2.

Studies on prevalence of postnatal depression.

Region/CountryAuthorsInstrumentsSample size (postnatal women)Time of assessment (after delivery)Study designStudy settingPrevalence (%)
America
USLevine et al. [24]ICD-9-CM (English)161,4548 weeks, 1 yearRetrospective cohortInformation from the Registry16.2
Stone et al. [25]PHQ-2 (English)5,3952, 6 monthsSurveys (secondary analysis)Massachusetts Pregnancy Risk Assessment Monitoring System (MA-PRAMS) 2007–2010 data14.9
Lynch and Prasad [26]PRAMS questionnaire (English)40,3372–4 monthsCross-sectional (secondary analysis)population-based national data from PRAMS13.3
Sidebottom et al. [27]PHQ-9 ≥ 10 (English)594≥ 4 weeksProspectiveCommunity health centres6
Abbasi et al. [28]EPDS ≥ 12 (English)29721 monthProspective cohortHospitals, obstetricians' offices and clinics, and targeted mailings5.1
Dolbier et al. [29]EPDS ≥ 10 (English)2991, 6 monthsCohortCommunity child health network17.5, 17.4
Pooler et al. [30]PHQ-2 (English)75,2342–6 monthsSurveys (secondary analysis)Pregnancy Risk Assessment Monitoring System (PRAMS) data13.8
Schachman and Lindsey [31]PDSS ≥ 14 (English)718 weeksComparative descriptiveMilitary Immunization Clinic50.7
Sweeney et al. [32]EPDS ≥ 12 (English)462 monthsProspective cohortObstetrics and gynaecology offices and midwifery offices10.9
Wisner et al. [33]EPDS ≥ 10 (English)10,0004–6 weeksSequential case seriesobstetric hospital14.0
Dagher et al. [34]EPDS (cut off point not mentioned) (English)5268 weeksProspective cohortHome interview6.5
Gress-Smith et al. [35]CES-D ≥ 24 (English)1325, 9 monthsLongitudinalHospital33, 38
Kornfeld et al. [36]US Preventive Services Task Force (English)392 monthsRetrospective (secondary analysis)Academic-based paediatric primary care clinic (new mothers survey data)15
384 months29
316 months26
Beck et al. [37]PDSS-Short Form ≥ 14 PHQ-2 (English)1,5661–12 monthsNational surveyHospital63
Gjerdingen et al. [38]PHQ-9 ≥ 10 (English)4642 monthsProspective cohortFamily medicine residency clinics and private paediatric clinics7.1
4594 months7.0
4556 months5.0
4729 months10.2
Wang et al. [39]CES-D ≥ 16 (English)1,364 families1LongitudinalHospitals25.6
6 months16.3
Murphy et al. [40]EPDS ≥ 10 (Translated, validated)974–6 weeksCohortPostnatal clinic12
Le et al. [41]PDSS ≥ 60 (Translated, validated by the researcher)2206–8 weeksLongitudinalClinics63.9
Sorenson et al. [42]BDI-II (English)716–7 monthsAn exploratory investigationDaily newspaper listing parent(s) name and city of residence15.7
Mcgrath et al. [43]EPDS ≥ 13 (English)1392, 6 monthsLongitudinal designCare provider's offices11, 15
CanadaVerreault et al. [44]EPDS ≥ 10 (English)2263 monthsCohortHealth centre and ultrasound department16.4
Dennis et al. [45]EPDS ≥ 13 (English)6,42112 weeksCross-sectional surveyData from the Maternity Experiences Survey of the Canadian Perinatal Surveillance System8
GreenlandMotzfeldt et al. [46]EPDS ≥ 13 (Translated, validated by the researcher)1743 monthsCross-sectionalPrimary health care8.6
ArgentinaMathisen et al. [47]EPDS ≥ 10 (Translated, validated)864–12 weeksCross sectionalPrivate health care centre37.2
BrazilRebelo et al. [48]EPDS ≥ 11 (Translated, validated)17730–45 daysProspective cohortAntenatal care unit16.9
Matijasevich et al. [49]EPDS ≥ 11 (Translated, validated)3,3323, 12 monthsCohortMaternity hospitals34.8, 40.9
Melo et al. [50]EPDS ≥ 12 (English)5554–6 weeksCross-sectionalPrenatal clinic of two public reference centres10.8
Lobato et al. [51]EPDS ≥ 12 (Translated, validated)81146–75 daysCross-sectionalPrimary health care units21.8
76–105 days37.5
106–135 days24.5
Pinheiro et al. [52]EPDS ≥ 10 (Translated, validated)3979–12 weeks, 12 monthsCohortBrazilian National System of Public Health22.7
36624.6
MexicoLara et al. [53]Structured Clinical Interview (SCID-I; PHQ ≥ 10 (Translated, validated by the researchers)2106 weeks, 6 monthsLongitudinalHospital and community centre11.4, 9.0
Africa
Ghana and IvoryGuo et al. [54]PHQ-9 ≥ 10 (Translated, validated)6543 and 12 monthsCohortHospital11.8, 16.1 and 8.9, 7.2
MoroccoAlami et al. [55]EPDS ≥ 13 M.I.N.I. (Translated, validated)100From the first trimester of pregnancy to 9 months after deliveryProspective cohort studyPrimary healthcare setting17
NigeriaAbiodun [56]EPDS ≥ 9 (Translated, validated by the researcher)3606 weeks postnatalCross sectionalPrimary health care18.6
South AfricaStellenberg and Abrahams [57]EPDS (cut off point not mentioned) (English)1596, 10 or 14 weeksCross-sectionalPrimary health care clinics50.3
SudanKhalifa et al. [58]EPDS ≥ 12 (Translated, validated by the researcher)2383 monthsCross-sectionalAntenatal clinic public tertiary hospitals9.2
Europe
EnglandLeahy-Warren et al. [59]EPDS ≥ 12 (English)410,3676, 12 weeksLongitudinalCommunity sample13.2, 9.8
FranceGaillard et al. [60]EPDS ≥ 12 (Translated, validated)2646, 8 weeksProspectivePublic maternity unit16.7
GreeceLambrinoudaki et al. [61]EPDS ≥ 11 (Translated, validated)576 weeksCross-sectionalUniversity hospital22.81
Koutra et al. [62]EPDS ≥ 13 (Translated, validated)4388 weeksProspective cohortMaternity clinics13
Leonardou et al. [63]GHQ, BDI and WHOQOL scores (Translated, validated)812 monthsProspective cohort studyMaternity hospitals12.4
GermanyGoecke et al. [64]EPDS ≥ 9 mild EPDS ≥ 12 medium to severe (Translated, validated)1596 monthsProspectiveObstetrics and gynaecology clinic10.1, 1.9
Zaers et al. [65]EPDS ≥ 13 (Translated, validated)476 weeks, 6 monthsProspective longitudinal studyHospital22, 21.3
HungaryKozinszky et al. [66]Leverton questionnaire (LQ) score of ≥ 12 (Translated, validated)Year 1996: 2,333Year 2006: 1,6196–10 weeksLongitudinalPregnancy-care centres15.017.4
ItalyElisei et al. [67]EPDS ≥ 13 (Not mentioned)853 monthsCohortObstetrics and gynaecology clinic16.7
Giardinelli et al. [68]EPDS ≥ 10 (Translated, validated)5903 monthsProspective cohortObstetrics and gynaecology clinic13.2
Banti et al. [69]EPDS ≥ 13 SCI DSM-IV (Translated, validated)1,0661, 3, 6, 9, 12 monthsLongitudinalHospital9.6
NetherlandsMeijer et al. [70]EPDS ≥ 10 (Translated, validated)1,2764–7 monthsProspective cohortObstetric care8.5
Meltzer-Brody et al. [71]EPDS ≥ 12 (Not mentioned)6824–12, 12 weeksLarge cohort studySubjects were from the Netherlands Study of Depression and Anxiety (NESDA)13, 10
NorwayGlavin et al. [72]EPDS ≥ 10 (Translated, validated)2,2276 weeks after deliveryCross-sectional studyWell baby clinics10.1
PortugalFigueiredo and Conde [73]EPDS ≥ 10 (Translated, validated)260 couples (260 women)10–14 weeksCohortObstetrics and gynaecology clinic11.1
Maia et al. [74]BDI-II ≥ 11, PDSS ≥ 633863-monthsLongitudinalLocal health medical centres13.0, 16.8
Marques et al. [75]Diagnostic Interview for Genetic Studies (DIGS), BDI-II (Translated, validated)3823 monthsCross-sectionalMother's local medical centre or homes11.5, 16.6
PolandDudek et al. [76]EPDS ≥ 12 (Translated, non-validated)3446, 12 weeksCross-sectionalObstetrics and gynaecology clinic16
SerbiaDmitrovic et al. [77]EPDS ≥ 12 Hamilton Depression Rating Scale (English)1956–8 weeksCross-sectionalObstetrics and gynaecology clinic11
SpainEscriba-Aguir and Artazcoz [78]EPDS ≥ 11 (Translated, validated)4203, 12 monthsLongitudinal cohortPrimary care centres9.3, 4.4
SwedenAgnafors et al. [79]EPDS ≥ 10 (Translated, validated)1,7073 monthsCohortChild welfare centres12.0
Kerstis et al. [80]EPDS ≥ 10 (Translated, validated)305 couples3 monthsCohortChild health centres16.5
11 study sites (Belgium, Germany, Italy, Poland and Spain)Grote et al. [81]EPDS ≥ 13 (English)9292, 3, 6 months postnatalCohort study11 study sites in five countries (specific study setting was not mentioned)6–8 (Germany and Spain)13–16 (Belgium, Poland and Italy)
Australia and New Zealand
AustraliaMcmahon et al. [82]M.I.N.I (English)4344 monthsProspective cohortAssisted reproductive technology (art) clinics8.3
Woolhouse et al. [83]EPDS ≥ 13 (English)1,5073, 6, 12 monthsCohortPublic hospital16.1
Wynter et al. [84]EPDS ≥ 9 (English)172 couples6 monthsCross sectionalLocal government areas12.2
Mcmahon et al. [85]M.I.N.I (English)5414 monthsProspective cohortAssisted reproductive technology clinics7.9
Austin et al. [86]EPDS score ≥ 13 CIDI (English)2352, 4, 6–8 monthsProspectiveObstetric hospital24.4, 32.8
Brooks et al. [87]EPDS ≥ 13 (English)4,8384, 8, 12, 16, 20, 24 weeksLarge cohort and prospective longitudinal designObstetric sites6.0–9.0
Bilszta et al. [88]EPDS ≥ 13 (English)1,958 urban 908 rural6th week postnatalCohort studyPerinatal health servicesUrban: 6.6Rural: 8.5
Milgrom et al. [89]EPDS ≥ 13 (English)12,3616th week postnatalA large prospective cohort studyMaternity hospital antenatal clinics7.5
New ZealandAbbott and Williams [90]EPDS ≥ 13 (Translated, validated by the researcher)1,3766 weeksCross-sectionalHospital and home visitsSamoans: 7.6Tongans: 30.9
Asia
ArmeniaPetrosyan et al. [91]EPDS ≥ 12 (Translated, validated by the researcher)4371–3 monthsCase-controlPrimary health care14.4
BahrainAl-Dallal et al. [92]EPDS ≥ 12 (Translated, validated by the researcher)2378 weeksCross-sectionalPrimary health care centres37.1
BangladeshEdhborg et al. [93]EPDS ≥ 10 (Translated, validated)6722–3 monthsCohortCommunity setting11
Gausia et al. [94]EPDS ≥ 10 (Translated, validated by the researcher)3466–8 weeksA community-based cohort studyMatlab subdistrict of rural Bangladesh22
ChinaDeng et al. [95]EPDS ≥ 10 (Translated, validated)1,8234 weeksCross-sectionalTangxia community27.4
Wu et al. [96]EPDS ≥ 11 (Translated, validated)2233 monthsLongitudinalObstetrics and gynaecology outpatient ward9.4
Mao et al. [97]EPDS ≥ 13 (Translated, validated)3766–8 weeksCross-sectionalPostpartum clinics14.9
Hong KongNgai et al. [98]GHQ ≥ 5 (Translated, validated)2006 monthsLongitudinalRegional hospital11.5
Lau et al. [99]EPDS ≥ 10 EPDS ≥ 15 (Translated, validated)6106 weeksLongitudinalObstetric outpatient clinics31.68.7
IndiaBodhare et al. [100]PHQ-9 (Translated, validated)2746–8 weeksCross-sectionalObstetrics and gynaecology clinic of a teaching hospital39.8
Johnson et al. [101]EPDS ≥ 13 (Translated, validated by the researcher)1236–8 weeksCross-sectionalMaternity hospital46.9
Shivalli and Gururaj [102]EPDS ≥ 13 (Translated, validated)1024–10 weeksCross-sectionalObstetrics and gynaecology clinic31.4
Gupta et al. [103]PRIME MD Today (PRIMary care evaluation of mental disorders) (Translated, validated)2026 weeksCross sectionalPostnatal clinic15.8
IranAbdollahi et al. [104]EPDS ≥ 13 (Translated, validated)1,9103 monthsLongitudinal cohortPrimary health centres19
Hosseni et al. [105]EPDS ≥ 13 (Translated, validated)4006 to 12 weeksCross-sectionalHealth centres40.4
Abbasi et al. [106]EPDS ≥ 13 (Translated, validated)4163 monthsProspective longitudinalTeaching university hospitals34.1
Sadat et al. [107]EPDS ≥ 13 (Translated, validated)3002 months and 4 monthsProspectiveHealth centres22.315.7
Goshtasebi et al. [108]EPDS ≥ 13 (Translated, validated)2544–6 weeksProspective studyHospital5.5
Taherifard et al. [109]EPDS ≥ 13 (Translated, validated)1796–8 weeksCross-sectionalObstetrics and gynaecology clinics34.8
Rouhi et al. [110]EPDS ≥ 13 (Translated, validated)4368 weeksCross-sectionalHealth care centres36.3
Kheirabadi et al. [111]EPDS ≥ 13(Translated, validated)1,8986 to 8Prospective cohortHealth centres26.3
IsraelAlfayumi et al. [112]EPDS ≥ 10 (Translated, validated)5644 weeks–7 monthsCross-sectionalMaternal and child health clinics31
Glasser et al. [113]EPDS ≥ 10 (Translated, validated)2,3266 weeksProspective cohortMaternal and child health clinics16.3
JapanShimizu et al. [114]EPDS ≥ 9 (Translated, validated)651, 4 monthsProspective cohortObstetrics clinics16.9, 7.7
Matsumoto et al. [115]EPDS ≥ 9 (Translated, validated)675≥ 3 monthsCohortUniversity hospital and maternity clinic14.8
Miyake et al. [116]EPDS ≥ 9 (Translated, validated)7713–4 monthsProspective cohortMunicipality of the domicile of the conception13.8
Mori et al. [117]EPDS ≥ 9 (Translated, validated)6755–7, 8–12 weeksCohortUniversity hospital4
JordanMohammad et al. [118]EPDS ≥ 13 (Translated, validated by the researcher)3536–8 weeks6 monthsProspective cross-sectionalTeaching hospital and health clinics22.1, 21.2
KoreaPark et al. [119]EPDS ≥ 10 (Translated, validated)1534 weeksLongitudinalMaternity clinics42.5
LebanonEl-Hachem et al. [120]EPDS ≥ 12 (Translated, validated)14930–40 postpartumCohortHospital12.8
MalaysiaYusuff et al. [121]EPDS ≥ 12 (Translated, validated)9791, 3, 6 monthsProspective cohortMaternal and child health clinics14.3
Zainal et al. [122]M.I.N.I (English)4116–8 weeksCross-sectionalPostnatal clinic, university hospital6.8
Kadir et al. [123]EPDS ≥ 12 (Translated, validated)2934–6 weeksCross sectional studyPostnatal clinic, hospital27.3
Azidah et al. [124]EPDS ≥ 12 (Translated, validated)4214–6 weeksCross sectional studyMaternal and child health clinics20.7
Wan Mohd Rushidi et al. [125]EPDS ≥ 12 BDI-II ≥ 10 CIDI HDRS ICD-I0 (Translated, validated)3544–12 weeksA two-stage population surveyHealth centres16.38
MongoliaPollock et al. [126]WHO Self Reporting Questionnaire (Translated, validated)1,0445 to 9 weeks postnatalCross-sectionalHospital/home visit9.1
NepalGiri et al. [127]EPDS ≥ 10 (Translated, validated)3466, 10 weeksCross-sectionalMaternity and women's hospital30
Budhathoki et al. [128]EPDS ≥ 13 (Not mentioned)726, 10 weeksProspective cohort studyTeaching hospital and district hospital19.4, 22.2
Ho-Yen et al. [129]EPDS ≥ 13 (Translated, validated)4265–10 weeks postnatalCross-sectional structured interview studyHospital's postnatal clinic, rural health posts, wards4.9
OmanAl Hinai and Al Hinai [130]EPDS ≥ 13 (Translated, validated)2828 weeksProspective cohortPrimary healthcare facilities10.6
PakistanHusain et al. [131]EPDS ≥ 12 (Translated, validated)763≥ 3 monthsCohort studyMaternity and child care centre38.3
Muneer et al. [132]EPDS ≥ 12 (Translated, validated)1546 weeks postnatalCross sectional studyOutpatient sample33.1
QatarBener et al. [133]EPDS ≥ 12 (Translated, validated)1,3796 monthsProspective cross-sectional studyPrimary healthcare centres17.6
Saudi ArabiaAlasoom and Koura [134]EPDS ≥ 10 (Translated, validated)4502–6 monthsCross-sectionalPrimary healthcare centres17.8
TaiwanTsao et al. [135]EPDS ≥ 13 (Translated, validated)1626 weeksLongitudinal cohortPostnatal clinic at regional hospitals24.1
Lee et al. [136]BDI-II ≥ 14 (Translated, validated)605–8 weeksCross-sectionalInfertility treatment centre25
TurkeyBolak Boratav et al. [137]EPDS ≥ 12 (Translated, validated)873–6 monthsLongitudinalObstetrics and gynaecology clinic48.3
Cankorur et al. [138]EPDS ≥ 13 (Translated, validated)5782, 6 monthsCohortMother and child centres26.1
Kirkan et al. [139]EPDS ≥ 13 (Translated, validated)3606 weeksProspectiveCity centre13.3
Turkcapar et al. [140]EPDS ≥ 14 (Translated, validated)5406–8 weeksProspectiveSpecialized tertiary obstetrics and gynaecology hospital15.4
Annagur et al. [141]EPDS ≥ 13 (Translated, validated)1976 weeksProspectiveUniversity hospital14.2
Poçan et al. [142]EPDS ≥ 13 (Translated, validated)1874–6 weeksCross-sectionalUniversity hospital28.9
Kirpinar et al. [143]EPDS ≥ 13 (Translated, validated)4796 weeksProspectivePrimary heath care centres14
Akyuz et al. [144]PDSS ≥ 65 (Translated, validated)1564–6 weeksCohortHospitals19.9
Dindar and Erdogan [145]EPDS ≥ 12 (Translated, validated)679 mothers1–12 monthsDescriptive designPublic health centres25.6
UAEHamdan and Tamim [146]EPDS ≥ 10, MINI (Translated, validated)1372 monthsProspectiveMaternal and child health centre5.9, 10.1
Green et al. [147]EPDS ≥ 13 (Translated, validated)86, 563, 6 monthsLongitudinal studyGovernment maternity hospital22, 12.5
VietnamMurray et al. [148]EPDS ≥ 13 (Translated, validated)4311–6 monthsCross-sectionalCommune health centre18.1

Italic: From initial review only.

Bold: Duplicates (both in initial and updated review).

There were wide variations in the screening instruments and diagnostic tools used, although the Edinburgh Postnatal Depression Scale (EPDS) was the most common instrument applied to identify maternal PND. All studies used self-report measure (e.g. EPDS, Patient Health Questionnaire (PHQ), Center for Epidemiological Studies Depression (CES-D) except 11 studies that used diagnostic interviews (e.g. Mini-International Neuropsychiatric Interview (MINI)) or International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10)). A total of 87 studies used translated versions (75 studies used the available translated and validated version, 11 studies used the version that was translated and validated by the authors themselves, and one used non-validated version), 34 studies used the original English version, and three studies did not clearly mention whether the measure was translated. Most studies included were cohort or cross sectional, however, study sample sizes and the timing of assessments varied (39-410 367 participants and 30 days to one year after giving birth) across the 124 studies. The total numbers of participants by continent are: Asia (28,718), North America (309,296), South America (5,934), Europe (426,219), Australia and New Zealand (13,737), and Africa (1,511). The majority of studies were conducted in community settings/outpatient maternity clinics, although there were also studies which analyzed data from large population-based surveys. Overall, the prevalence of PND ranged from 4.0% to 63.9%, with Japan and America recording the lowest and highest rates of PND, respectively [9],[41]. Within continents, a wide variation in reported prevalence was also found. The prevalence of PND varied from 4.0–48.3% in Asia [117],[137], 5.0–63.9% in America [38],[41], 4.4–22.8% in Europe [78],[61], 7.2–50.3% in Africa [54],[57], 6.0–32.8% in Australia [86],[87], and 7.6–30.9% in New Zealand [90]. Wide variations in the rates of PND have also been reported within Asian countries. For instance, the reported prevalence of PND ranged from 15.8–46.9% in India [101],[103] and 9.4–27.4% in China [95],[96]. In Malaysia, the prevalence of PND ranged from 6.8–27.3% [122],[123]. A total of five Malaysian studies were published between 2006 and 2016 and were included in this review. The prevalence reported in these studies differed as there were differences in study instruments, sample size, time of assessment, study design, and study setting. The EPDS with a cut-off point of 12 was used in all studies except one [122]. The times of assessments used to assess PND in these studies were 4–6 months following childbirth. The sample sizes ranged from 293–979 with a total of 2458 postnatal women involved in the five studies. Three of the studies used a cross sectional design; one was a prospective cohort and one was a population survey. Three of these Malaysian studies were conducted in maternal and child health (MCH) clinics, whereas two of them were conducted in postnatal clinics at a teaching hospital. Whilst three of these studies focussed mainly on Malay women, two included women from other cultural backgrounds, such as Chinese, Indian, and other ethnic minorities. Italic: From initial review only. Bold: Duplicates (both in initial and updated review).

Discussion and conclusion

This review found that the prevalence of PND ranged from 4.0–63.9% with Japan and America recording the lowest and highest rates of PND, respectively [9],[10]. Within continents, a wide variation in reported prevalence was also found. This finding is consistent with an earlier finding of a review of 143 studies across 40 countries that identified that the prevalence of PND ranged from 0–60% [21]. As with that review, this present review also indicated that the widely-cited prevalence of PND of 10–15% [149] does not represent the actual magnitude of PND problems worldwide. However, it should be noted that prevalence reported within this review was mainly based on self-report measures. Self-report measures have been found to give higher prevalence estimates than diagnostic tools [150]. This could explain the higher range of the prevalence reported in this study compared to the previous review. Prevalence of PND can also vary depending on when the assessment is performed. For instance, assessing depressive symptoms in the postnatal period may inadvertently capture the common physiological or emotional responses to pregnancy and caring for an infant. Therefore, selective use of specific tools to screen women at higher risk for postpartum depression is recommended [151]. The willingness of a woman to admit to symptoms of PND may also influence the reported prevalence and this can vary across cultures as the label of PND may be unacceptable in some groups and may not be used at all [19]. Studies that have aimed to understand women's experiences and perceptions of PND have suggested that the majority of women were reluctant to disclose their depressive symptoms to healthcare providers [12],[13],[152]. There were many reasons why women did not reveal their inner turmoil but these were commonly linked with the stigmatization of a PND diagnosis, such as concern that it would make them “feel weak”, fear they would be judged as a “bad mother”, and fear of having their children referred to social services [152]. Stigma related to PND was found across a range of cultures and appeared to contribute to the women's feelings of being “viewed differently” from other mothers in their culture [153]–[155]. Although the reasons for the wide range of prevalence shown in this present review may also be explained by inconsistency in the estimated sensitivity and specificity of the EPDS (used in the majority of the studies in this review), it could also be linked to cross-cultural differences and the way in which women understand and interpret items in the EPDS. The EPDS was designed specifically by Cox et al. [156] to identify symptoms of PND. The EPDS consists of 10 statements describing depressive symptoms with some reverse coded items with four possible responses, 0, 1, 2, and 3, with each score relating to PND symptoms severity or duration. The total score is calculated by adding together the scores for each of the ten items with an overall score ranging from 0 to 30. Cut off scores for screening are typically set at ≥ 10 or ≥ 13. The reliability and validity of the Malay version of the EPDS has been verified [157],[158]. It was found to have good internal consistency with Cronbach's alpha 0.86, and split half reliability with Spearman split half coefficient 0.83 [158]. The score of 11.5 represents the optimum cut-off point for 72.7% sensitivity, 95% specificity, and a positive predictive value of 80% [157]. The cut off of 11/12 was recommended to identify a woman at risk of developing PND [121],[158]. Whilst it is understandable that the process of translation of the instruments and attempts to maintain the homogeneity of the interpretation of the questions had been considered, some cultures may define unique clusters of symptoms that differ from the western concept of PND [159]. Malaysia, a multi-ethnic country located in Southeast Asia comprises of three main races, including Malay (53.3%), Chinese (26.0%) and Indian (7.7%) [160]. Malaysia has a wide-range of cultural and ethnic backgrounds and this offers an ideal opportunity to understand the different role of cultures and postnatal practices in relation to PND. There are some small differences in postnatal practices among the three main cultures in Malaysia, such as in defining the period of the confinement. Within the Malaysian communities, the postnatal period is commonly referred to as postnatal confinement. In Malay society, the postnatal period is called masa dalam pantang [161] and both mother and baby are expected to remain house-bound for around 44 days. In Chinese communities, the postnatal period is the point from the baby's birth up to one month later, whereas the postpartum period in the Indian community refers to the period after the childbirth until between 30 and 40 days later [162]. Given that Malaysian's women have different cultural backgrounds compared to western cultures, the standard measurements that have been developed within western cultures like the EPDS, may not capture the localised expressions of depressive symptoms, and therefore lack conceptual equivalence. It may be possible that the women across cultures have different explanations of their PND experience which may go beyond the 10 items included in the EPDS. Although there are questionnaires available to assess postnatal mental illness, these were generated based on western women's experiences which may not fully represent the signs and symptoms experienced by Malaysian women. Using any of these tools to detect postnatal mental illness among Malaysian women may therefore not be valid. The prevalence of PND in Malaysia ranged from 6.8–27.3%, which has shown that the cases of PND were not as low as had initially been reported by two earlier reviews [20],[21]. In their international review of prevalence of PND, Halbreich and Karkun [21] reported that there were very few reports of PND in Malaysia with a rate of only 3.9%. Similarly, Klainin and Athur [20] stated that the prevalence of PND in Malaysia was only 3.5%, the lowest prevalence reported in Asian countries. Their finding was based on the review of 64 studies from 17 Asian countries conducted between 1998 and 2008. Both reviews presented their findings based on the only one Malaysian study published in 1997 [163]. This study was the earliest published study on the prevalence of PND in Malaysia. Kit et al. [163] conducted their study among 154 postnatal women from three main Malaysian cultural backgrounds; Malay, Chinese and Indian and reported that the rate of PND in Malaysia was 3.9%. There was a recent review by Norhayati et al. [164] that reported that the prevalence of PND in Malaysia at 4–6 weeks was 20.7%, but they also based this on only one study. The prevalence of PND reported in this present review was based on the results of five current studies in Malaysia, and this may increase confidence in the findings. It seems clear that the rates of PND in Malaysia are not as low as reported by the international and Asian studies. Yet it is still unclear whether the wide range of reported prevalence of PND is due to variation in actual cases or to incorrect reports caused by use of instruments to diagnose PND that are inappropriate to the population and culture in Malaysia where, for example, there may be the stigma of a socially unacceptable reaction. Although the instruments used in the studies of the prevalence of PND (such as the EPDS) were translated into the Malay language items covered in these instruments may not fully match Malaysian understanding of PND. Therefore, there is a need for a screening scale that can measure the symptoms of PND as experienced by Malaysian women. Despite contributing to understanding of the scale of PND problems across 50 countries, this review has four limitations that should be addressed. First, it only included the English/Malay articles in the chosen databases, which may have limited the generalisability of the findings. Second, the methodological quality of the included papers was not assessed, therefore the time of assessment of PND and inclusion criteria (such as maternal age, presence of medical and obstetrical problems, and socioeconomic status) varied across the studies. However, an effort has been made to include only rates reported after four weeks postnatal, therefore minimising the possibility of the inclusion of postnatal blues instead of PND. Third, this study did not conduct a meta-analysis of the prevalence. Fourth, this study uses two different sets of search terms, which may have resulted in some missed studies during the much more limited original review. Overall, the reported rates of PND in Malaysia are much higher than that previously documented with a range of 6.8–27.3%. The reasons of this variability may not be fully explained using review methods. It is unclear whether variation is due to variation in actual cases or to the use of inappropriate instruments in assessing PND. This review recommends a meta-analysis study and a complementary qualitative study that could explain the nature of PND experience in Malaysia and address reasons for reported variation in prevalence.
  145 in total

1.  Perinatal depression: a study of prevalence and of risk and protective factors.

Authors:  Sandro Elisei; Emanuela Lucarini; Nicola Murgia; Laura Ferranti; Luigi Attademo
Journal:  Psychiatr Danub       Date:  2013-09       Impact factor: 1.063

Review 2.  Prevalence of paternal depression in pregnancy and the postpartum: An updated meta-analysis.

Authors:  Emily E Cameron; Ivan D Sedov; Lianne M Tomfohr-Madsen
Journal:  J Affect Disord       Date:  2016-07-20       Impact factor: 4.839

3.  Examining relationships between body dissatisfaction, maladaptive perfectionism, and postpartum depression symptoms.

Authors:  Alison C Sweeney; Randy Fingerhut
Journal:  J Obstet Gynecol Neonatal Nurs       Date:  2013-09-04

4.  The association between sociodemographic characteristics and postpartum depression symptoms among Arab-Bedouin women in Southern Israel.

Authors:  Samira Alfayumi-Zeadna; Vered Kaufman-Shriqui; Atif Zeadna; Ari Lauden; Ilana Shoham-Vardi
Journal:  Depress Anxiety       Date:  2014-07-10       Impact factor: 6.505

5.  From the third month of pregnancy to 1 year postpartum. Prevalence, incidence, recurrence, and new onset of depression. Results from the perinatal depression-research & screening unit study.

Authors:  Susanna Banti; Mauro Mauri; Annalisa Oppo; Chiara Borri; Cristina Rambelli; Daniele Ramacciotti; Maria S Montagnani; Valeria Camilleri; Sonia Cortopassi; Paola Rucci; Giovanni B Cassano
Journal:  Compr Psychiatry       Date:  2010-09-23       Impact factor: 3.735

6.  Prevalence and risk factors of maternal depression during the first three years of child rearing.

Authors:  Liang Wang; Tiejian Wu; James L Anderson; James E Florence
Journal:  J Womens Health (Larchmt)       Date:  2011-03-22       Impact factor: 2.681

7.  Epidemiology of postpartum depressive symptoms among Canadian women: regional and national results from a cross-sectional survey.

Authors:  Cindy-Lee Dennis; Maureen Heaman; Simone Vigod
Journal:  Can J Psychiatry       Date:  2012-09       Impact factor: 4.356

8.  Depressive symptoms and symptoms of post-traumatic stress disorder in women after childbirth.

Authors:  Stefanie Zaers; Melanie Waschke; Ulrike Ehlert
Journal:  J Psychosom Obstet Gynaecol       Date:  2008-03       Impact factor: 2.949

9.  Sociodemographic and clinical features of postpartum depression among Turkish women: a prospective study.

Authors:  Ayse Figen Turkcapar; Nezaket Kadıoğlu; Ebru Aslan; Suphi Tunc; Müjdegül Zayıfoğlu; Leyla Mollamahmutoğlu
Journal:  BMC Pregnancy Childbirth       Date:  2015-05-03       Impact factor: 3.007

10.  Poor sleep quality of third-trimester pregnancy is a risk factor for postpartum depression.

Authors:  Meifen Wu; Xiaoyi Li; Bin Feng; Hao Wu; Chunbo Qiu; Weifeng Zhang
Journal:  Med Sci Monit       Date:  2014-12-20
View more
  17 in total

1.  The hormonal keys to depression.

Authors:  Bianca Nogrady
Journal:  Nature       Date:  2022-08       Impact factor: 69.504

2.  Prevalence and risk factors of postpartum depression among women living in the United Arab Emirates.

Authors:  Nivine Hanach; Hadia Radwan; Randa Fakhry; Cindy-Lee Dennis; Wegdan Bani Issa; MoezAlIslam E Faris; Reyad Shaker Obaid; Suad Al Marzooqi; Charbel Tabet; Nanne De Vries
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2022-10-14       Impact factor: 4.519

3.  Occurrence and determinants of parental psychosocial stress and mental health disorders in parents and their children in early childhood: rationale, objectives, and design of the population-based SKKIPPI cohort study.

Authors:  J Fricke; M Bolster; C Ludwig-Körner; L Kuchinke; F Schlensog-Schuster; P Vienhues; T Reinhold; A Berghöfer; S Roll; T Keil
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2020-12-18       Impact factor: 4.328

4.  Preventing postnatal depression: a causal mediation analysis of a 20-year preconception cohort.

Authors:  Elizabeth A Spry; Margarita Moreno-Betancur; Melissa Middleton; Louise M Howard; Stephanie J Brown; Emma Molyneaux; Christopher J Greenwood; Primrose Letcher; Jacqui A Macdonald; Kimberly C Thomson; Ebony J Biden; Craig A Olsson; George C Patton
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2021-05-03       Impact factor: 6.671

5.  Re-examination of perinatal mental health policy frameworks for women signalling distress on the Edinburgh Postnatal Depression Scale (EPDS) completed during their antenatal booking-in consultation: a call for population health intervention.

Authors:  Sarah Khanlari; Bryanne Barnett Am; Felix Akpojene Ogbo; John Eastwood
Journal:  BMC Pregnancy Childbirth       Date:  2019-07-02       Impact factor: 3.007

6.  Postpartum Depression: A Case Report of Bedapu From Aceh Singkil.

Authors:  Belli Susandro Pinem; Elmeida Effendy
Journal:  Open Access Maced J Med Sci       Date:  2019-08-30

7.  Psychosocial and obstetric determinants of women signalling distress during Edinburgh Postnatal Depression Scale (EPDS) screening in Sydney, Australia.

Authors:  Sarah Khanlari; John Eastwood; Bryanne Barnett; Sabrina Naz; Felix Akpojene Ogbo
Journal:  BMC Pregnancy Childbirth       Date:  2019-11-07       Impact factor: 3.007

8.  Prevalence and associated factors of post-partum depression in Ethiopia. A systematic review and meta-analysis.

Authors:  Tadele Amare Zeleke; Wondale Getinet; Zemenu Tadesse Tessema; Kassahun Gebeyehu
Journal:  PLoS One       Date:  2021-02-19       Impact factor: 3.240

9.  The role of intimate partner violence victimization during pregnancy on maternal postpartum depression in Eastern Ethiopia.

Authors:  Wondimye Ashenafi; Bezatu Mengistie; Gudina Egata; Yemane Berhane
Journal:  SAGE Open Med       Date:  2021-01-23

10.  The Malaysian Women's Experience of Care and Management of Postnatal Depression.

Authors:  Siti R B M Arifin; Helen Cheyne; Margaret Maxwell; Abdilahi Yousuf
Journal:  Clin Pract Epidemiol Ment Health       Date:  2021-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.